- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Elicera Therapeutics AB: Elicera Therapeutics Receives Safety Committee Recommendation to Use Highest ELC-301 Dose as CARMA Moves Toward Phase IIa in B-cell Lymphoma | 161 | GlobeNewswire (Europe) | Uppsala, September 9, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 01.09. | Elicera Therapeutics AB: Elicera Therapeutics receives its first notice of patent allowance for ELC-201 - a Japanese patent protecting the oncolytic virus candidate against solid tumors | 143 | GlobeNewswire (Europe) | Uppsala, September 1, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate | 561 | GlobeNewswire (Europe) | Gothenburg, August 28, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 28.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2026 | 194 | GlobeNewswire (Europe) | Second quarter (January-March 2026)
Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
Loss for the period amounted to SEK -6,261,763 (-2,732,070)
Cash flow from operating activities... ► Artikel lesen | |
| 18.08. | Elicera Therapeutics AB: Elicera Therapeutics appoints Johan Liwing as new CEO | 507 | GlobeNewswire (Europe) | Gothenburg, August 18, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.08. | ELICERA THERAPEUTICS AB: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 1 | Cision News | ||
| 11.08. | Elicera Therapeutics AB: Elicera Therapeutics: Last patient treated in the Phase I part of the CARMA study - tumor responses in 10 of 11 patients evaluated to date | 261 | GlobeNewswire (Europe) | Gothenburg, August 11, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 24.07. | Elicera Therapeutics AB: Elicera Therapeutics consolidates its management in Uppsala - CEO transition begins and recruitment of new CEO has started | 188 | GlobeNewswire (Europe) | Gothenburg, July 24, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma | 1 | Cision News | ||
| 03.06. | ELICERA THERAPEUTICS AB: Elicera publishes annual report for 2025 | 1 | Cision News | ||
| 01.06. | Elicera Therapeutics AB: Elicera announces outcome of the rights issue | 339 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 25.05. | Elicera Therapeutics AB: Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved | 488 | GlobeNewswire (Europe) | Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 13.05. | Elicera Therapeutics AB: Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO | 246 | GlobeNewswire (Europe) | Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 12.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.05.2026 | 1.460 | Xetra Newsboard | Das Instrument MIH0 US6067934041 MITSUBISHI HEAV.IN. ADR/1 EQUITY wird cum Kapitalmassnahme gehandelt am 12.05.2026 und ex Kapitalmassnahme am 13.05.2026 The instrument MIH0 US6067934041 MITSUBISHI... ► Artikel lesen | |
| 11.05. | Elicera Therapeutics AB: Elicera publishes information document regarding the rights issue | 391 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics carries out a rights issue of approximately SEK 73 million | 308 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, ISRAEL, CANADA, JAPAN, SOUTH AFRICA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 21.04. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026 | 226 | GlobeNewswire (Europe) | First quarter (January-March 2026)
Operating profit/loss amounted to SEK -5,116,779 (-8,069,404).
Loss for the period amounted to SEK -5,060,060 (-8,013,462).
Cash flow from operating activities... ► Artikel lesen | |
| 20.03. | Elicera Therapeutics AB: Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu | 368 | GlobeNewswire (Europe) | Gothenburg, March 20, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 11.03. | Elicera Therapeutics AB: Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate | 234 | GlobeNewswire (Europe) | Gothenburg, March 11, 2023 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells... ► Artikel lesen | |
| 06.03. | Elicera Therapeutics AB: Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients | 296 | GlobeNewswire (Europe) | Gothenburg, March 6, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,968 | -2,50 % | Evotec erreicht wichtigen Meilenstein: US-Verteidigungsprogramm bringt JST-018 in die klinische Phase | Evotec gibt es einen wichtigen operativen Fortschritt im Biologika-Geschäft: Die Tochtergesellschaft Just - Evotec Biologics startet mit dem Antikörperkandidaten JST-018 eine klinische Phase-I-Studie.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 676,90 | +0,45 % | Here's Why The Fund Sold Regeneron Pharmaceuticals (REGN) | ||
| BRAIN BIOTECH | 2,810 | -0,71 % | Brain Biotech: Meilensteinzahlung naht | Pharvaris hat positive Daten aus einer zulassungsrelevanten Phase-3-Studie zu Deucrictibant zur Prophylaxe von HAE-Anfällen publiziert. Der primäre Endpunkt wird klar erreicht. Die Daten aus der Studie... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,796 | +4,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| CSL | 103,14 | +0,10 % | Dividendenbekanntmachungen (09.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,319 HKD 0,0349 EUR ANHUI CONCH CEMENT CO LTD ADR US0352431045 0,0958 USD 0,0824... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,900 | 0,00 % | Burcon NutraScience Corporation: Burcon Announces Annual General and Special Meeting Date | Company upsizes convertible debenture financing from $8.1 million to $21 million following strong investor interestVancouver, British Columbia--(Newsfile Corp. - September 4, 2026) - Burcon NutraScience... ► Artikel lesen | |
| MANNKIND | 3,205 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,200 | +1,10 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,865 | +1,75 % | Oxford Nanopore Tech - Participation in upcoming investor conferences | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,243 | -1,66 % | Codexis, Inc.: Codexis Reports Second Quarter 2026 Financial Results | Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO... ► Artikel lesen | |
| CORMEDIX | 7,162 | +6,14 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| TELO GENOMICS | 0,017 | +3.300 % | Telo Genomics Corp.: Telo Genomics Grants Stock Options | Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 4,950 | +10,24 % | Aligos-Aktie +37%: Ein Vorbote für mehr? | Die Aligos-Aktie ist zum Wochenauftakt förmlich explodiert und schloss unter beachtlichen Umsätzen rund +37% höher. Für Anleger unserer Community ist das ein Déjà-vu: Bereits in der Vergangenheit haben... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,254 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.